The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
The EAP applies to patients not eligible to ongoing GS010 clinical trials.
Presence of documented G11778A ND4 LHON-causing mutation
Signature of informed consent and assent from the parent/guardian and the patient.
Contraindications to GS010 product or IVT procedures are to be checked prior to consent signature and treatment injection:
Any known allergy or hypersensitivity to GS010 or its constituents.
Contraindication to intravitreal injection in any eye.
Intravitreal drug delivery to any eye within 30 days prior to the injection
Previous vitrectomy in either eye.
Narrow angle in any eye contra-indicating pupillary dilation.
Presence of disorders or diseases of the eye or adnexa, excluding LHON, which may interfere with visual or ocular assessments, including SD-OCT, during the study period.
Presence of known/documented mutations, other than the G11778A ND4 LHON-causing mutation, which are known to cause pathology of the optic nerve, retina or afferent visual system.
Presence of systemic or ocular/vision diseases, disorders or pathologies, other than LHON, known to cause or be associated with vision loss, or whose associated treatment(s) or therapy(ies) is/are known to cause or be associated with vision loss.
Presence of optic neuropathy from any cause except LHON.
Presence of illness or disease that, in the opinion of the Investigator, include symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the central nervous system, including Multiple Sclerosis (diagnosis of Multiple Sclerosis must be based on the 2010 Revisions to the McDonald Criteria [Polman 2011]).
History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation.
Previous treatment with ocular gene therapy in either eye.
Subjects who have undergone ocular surgery of clinical relevance (per Investigator assessment) within 90 days prior to injection.
Subjects who are unable to tolerate (e.g. the immune modulating regimen) or unable or unwilling to comply with all the protocol requirements.